Sweden · Delayed Price · Currency is SEK Xintela AB Company Description
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy.
The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses.
It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
It has an agreement with Region Östergötland for GMP process development of cell therapy for burn patients.
Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
| Country | Sweden |
| Founded | 2009 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Evy Lundgren-Åkerlund |
Contact Details
Address: Medicon Village Lund, 223 81 Sweden | |
| Phone | 46 4 62 75 65 00 |
| Website | xintela.se |
Stock Details
| Ticker Symbol | XINT |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0007756903 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D. | Chief Executive Officer |
| Gregory Batcheller B.Sc., J.D., L.L.M. | Executive Chairman of the Board |
| Gunnar Telhammar | Chief Financial Officer and Finance Director |
| Peter Ekolind | Chief Operating Officer and Vice President of Commercial Manufacturing |
| Lucienne Vonk | Chief Scientific Officer |
| Dr. Per Goran Oskar Norlen M.D., Ph.D. | Chief Medical Officer |
| Camilla Wennersten | Director of Clinical Development |